Targeting KIR Blockade in Multiple Myeloma: Trouble in Checkpoint Paradise?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 27430580.
- Also identified by PMC identifier 5093060.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Findings within the current issue indicate that treatment with IPH2101 when used as a monotherapy in smoldering multiple myeloma, meant to enhance natural killer (NK) cell function through inhibitory KIR blockade, results in a surprising reduction of NK-cell function mediated through monocyte trogocytosis. The significance of these findings is discussed. Clin Cancer Res; 22(21); 5161-3. ©2016 AACRSee related article by Carlsten et al., p. 5211.
Medical subject headings
- Multiple Myeloma
- Receptors, KIR